Male Hypogonadism Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Male Hypogonadism Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global market for male hypogonadism is on the verge of substantial growth, spurred by increasing awareness and the availability of effective treatment options. Male hypogonadism, characterized by the lack of sex hormones, presents several health risks, including osteoporosis and heart disease due to the thinning of bones. The market features numerous patented brands with significant market penetration, supported by a growing geriatric population and rising incidences of rheumatoid arthritis and obesity.

Mounting Cases of Testosterone Deficiency

A crucial factor contributing to the prevalence of male hypogonadism worldwide is the rising number of testosterone deficiency cases among men. Governments globally are actively promoting awareness about hypogonadism treatment methods, including testosterone replacement therapy (TST), among patients. This initiative aims to mitigate the exacerbation of chronic conditions associated with low testosterone levels and disorders related to the hypothalamic-pituitary-gonadal axis.

The Impact of Testosterone Replacement Therapy

The introduction of TST has helped reduce the number of male hypogonadism cases to some extent. With growing awareness about the treatment, the market is expected to gain momentum in the near future. Additionally, the availability of selective androgen receptor modulators (SARMs) is anticipated to accelerate market expansion. The development and availability of SARMs have provided improved treatment procedures for patients with androgen deficiencies, further contributing to market growth.

Steady Market Expansion

According to a new report by Fairfield Market Research, the global male hypogonadism market is projected to experience steady expansion from 2017 to 2026. The market is forecast to surpass significant revenue milestones by the end of 2026, driven by increased awareness and the introduction of advanced treatment options.

Topical Gels to Dominate Market Revenue

Based on drug type, topical gels are expected to continue accounting for the largest revenue share in the global male hypogonadism market. Available in a semi-liquid state, topical gels contain an active ingredient that can be applied locally, offering maximum efficacy. The ease of application and removal has further boosted their demand among patients. Conversely, transdermal patches are anticipated to account for the smallest revenue share during the forecast period.

North America Leading the Market

In North America, a relatively higher prevalence of chronic diseases is observed due to lower testosterone levels in the region’s male population. This has created a high demand for testosterone replacement therapy, significantly contributing to the region’s revenue share in the male hypogonadism market. North America is expected to remain dominant in terms of revenues and is projected to exhibit the highest compound annual growth rate (CAGR) through 2026.

Key Research Findings

Fairfield Market Research's report highlights several key findings:
• Therapy Type: Testosterone replacement therapy will continue to lead the global male hypogonadism market in terms of revenues.
• Disease Type: Klinefelter’s syndrome will account for a relatively larger revenue share during the forecast period.

Market Competition and Strategic Alliances

The global male hypogonadism market is highly competitive, characterized by the presence of numerous small and large suppliers. Occasional competition eruptions are observed from local manufacturers in various countries. New companies are entering the market as treatment developments and innovations present numerous opportunities for these players. Strategic alliances will remain key among vendors to produce and market drugs worldwide, expanding their market reach.

Key Players in the Market

The report identifies several key players in the global male hypogonadism market, including:
• IBSA Institut Biochimque
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company Ltd.
• Ferring
• Allergan Plc.
• Merck & Co. Inc.
• Bayer AG
• Finox Biotech
• AbbVie Inc.
• Endo International Plc.
• Laboratories Genevrier
• AstraZeneca Plc.

Global Male Hypogonadism market is Segmented as Below:

By Therapy:
• Testosterone Replacement Therapy
• Gonadotropin Replacement Therapy

By Drug Type:
• Topical Gels
• Injectables
• Transdermal Patches
• Others

By Disease Type:
• Klinefelter's Syndrome
• Pituitary Adenomas
• Kallmann Syndrome
• Other Types

By Region:
• North Americ
• Latin America
• Europe
• Japan
• APEJ
• MEA

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.